Geneious

Executive Summary

Geneious is a privately held bioinformatics software company headquartered in Auckland, New Zealand, with 50–200 employees. Founded in 2005, it provides a comprehensive suite for sequence analysis, molecular biology, and genomics research, serving academic institutions and biotechnology companies globally. The platform integrates AI and machine learning to streamline data processing, annotation, and visualization, making it a staple in genomics workflows. Despite being a well-established tool in the research community, Geneious operates in a competitive landscape dominated by larger players and open-source alternatives. Its commercial focus and subscription-based model provide recurring revenue, but limited public financial data and the absence of disclosed funding rounds suggest a steady, self-sustaining growth trajectory. The company's private status limits visibility into its valuation and market share, but its sustained presence in the bioinformatics space indicates resilience and a loyal user base.

Upcoming Catalysts (preview)

• Q3 2026Launch of AI-Powered Variant Interpretation Module60% success
• Q4 2026Strategic Partnership with Major Pharmaceutical Company40% success
• Q2 2026Release of Cloud-Based Collaborative Platform55% success